webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Val-Cit

  CAS No.: 159858-33-0   Cat No.: BADC-00969   Purity: >98.0% 4.5  

Val-Cit is a widely used cleavable dipeptide ADC linker enabling protease-sensitive payload release. Essential for antibody-drug conjugate development targeting tumor-specific environments with high therapeutic precision.

Val-Cit

Structure of 159858-33-0

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C11H22N4O4
Molecular Weight
274.32
Shipping
Room temperature, or blue ice upon request.
Storage
Store at -5°C,keep in dry and avoid sunlight.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
Valyl-citrulline
IUPAC Name
Canonical SMILES
CC(C)C(C(=O)NC(CCCNC(=O)N)C(=O)O)N
InChI
InChI=1S/C11H22N4O4/c1-6(2)8(12)9(16)15-7(10(17)18)4-3-5-14-11(13)19/h6-8H,3-5,12H2,1-2H3,(H,15,16)(H,17,18)(H3,13,14,19)/t7-,8-/m0/s1
InChIKey
AGGWFDNPHKLBBV-YUMQZZPRSA-N
Solubility
10 mm in DMSO
Appearance
Solid
Shelf Life
0-4°C for short term (days to weeks), or -20°C for long term (months).
Shipping
Room temperature, or blue ice upon request.
Storage
Store at -5°C,keep in dry and avoid sunlight.
Form
Solid

Val-Cit is a widely used cleavable linker in antibody-drug conjugate (ADC) design, featuring a valine-citrulline dipeptide sequence that enables selective intracellular payload release. In ADC linker design, Val-Cit acts as a protease-sensitive cleavable unit, allowing controlled release of ADC cytotoxins specifically within lysosomal compartments of tumor cells. Its chemical structure ensures high stability in circulation while maintaining efficient cleavage upon internalization. Val-Cit’s incorporation into ADCs enhances modular linker design, allowing the attachment of diverse payloads while preserving antibody functionality and pharmacokinetic performance.

In payload conjugation applications, Val-Cit is compatible with a broad spectrum of ADC cytotoxins, including microtubule inhibitors, DNA-intercalating agents, and other potent therapeutic molecules. The dipeptide sequence is selectively cleaved by cathepsin B and other lysosomal proteases, providing tumor-specific payload release. Val-Cit can be combined with various linker architectures, such as PEG spacers or self-immolative PABA groups, to optimize solubility, flexibility, and stability. Researchers leverage Val-Cit to construct homogeneous ADCs with predictable release profiles, enhancing both efficacy and safety in preclinical and clinical development.

From an application perspective, Val-Cit is extensively applied in oncology-focused ADC research, targeted drug delivery studies, and protease-sensitive bioconjugation strategies. Its unique dipeptide structure enables highly selective payload release while maintaining linker stability in circulation. By integrating Val-Cit into ADC linker design, developers can create tunable, cleavable linker-payload conjugates that maximize therapeutic potential, providing precise intracellular delivery tailored to the tumor microenvironment without compromising antibody integrity.

What is the primary application of Val-Cit in ADCs?

Val-Cit is a dipeptide linker commonly used in antibody-drug conjugates, designed to be cleaved by cathepsin B and related proteases in lysosomal compartments, ensuring selective payload release.

1/5/2022

Dear team, how does Val-Cit ensure selective release of cytotoxins?

The Val-Cit linker remains stable in circulation but is efficiently cleaved by lysosomal proteases within target cells, providing a high degree of specificity and minimizing systemic toxicity.

29/8/2020

Could you kindly advise which types of ADC payloads are compatible with Val-Cit?

Val-Cit is compatible with a variety of cytotoxic agents, including MMAE and other auristatin derivatives, through carbamate or amide linkage strategies without altering antibody function.

16/3/2022

Dear Sir, what factors should be considered when optimizing Val-Cit linkers?

Optimization factors include peptide sequence confirmation, linker length, steric hindrance effects, and evaluation of intracellular cleavage rates to maximize therapeutic efficacy.

8/6/2019

Good afternoon! Which detection and verification methods would you suggest for Val-Cit?

Val-Cit identity and structural integrity can be confirmed using NMR, HPLC, and mass spectrometry. Proper storage at -20°C under dry conditions is recommended to maintain dipeptide stability. Aliquoting reduces the risk of degradation, ensuring reliable performance in antibody-drug conjugate applications.

12/5/2018

— Dr. Natalie Brown, Bioconjugation Scientist (USA)

Val-Cit linker demonstrated excellent enzymatic cleavage, ensuring precise payload release in ADCs.

16/3/2022

— Prof. Henrik Larsen, Medicinal Chemist (Denmark)

High batch-to-batch reproducibility of Val-Cit made scaling our ADC program seamless.

12/5/2018

— Dr. Sofia Moretti, Protein Chemist (Italy)

BOC Sciences’ Val-Cit linker showed consistent quality and high purity, facilitating conjugation.

8/6/2019

— Ms. Emily Thompson, R&D Manager (UK)

Using Val-Cit linker, we achieved reproducible conjugation yields with minimal side reactions.

1/5/2022

— Dr. Marcus Schmidt, Bioconjugation Specialist (Germany)

Excellent solubility and stability profile of Val-Cit improved our workflow efficiency.

— Mr. Daniel Johnson, Research Scientist (Canada)

Val-Cit linker facilitated high-throughput ADC screening with reliable payload release.

29/8/2020

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: 2,5-dioxopyrrolidin-1-yl 3-(2-(2-(2-(1,3-dioxoisoindolin-2-yloxy)ethoxy)ethoxy)ethoxy)propanoate | Ald-Ph-amido-PEG23-OPSS | S-Me-DM4 | Bocaminooxyacetamide-PEG2-Azido | 5-hexynoic NHS ester | Gly-Gly-Gly-PEG4-DBCO | FSP-2 | FSP-3 | FSP-1 | 2,5-Dioxopyrrolidin-1-yl 3-((2-Fluorobenzyl)oxy)propanoate | Val-Cit
Send Inquiry
Verification code
Inquiry Basket